<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384329</url>
  </required_header>
  <id_info>
    <org_study_id>RESV-depression</org_study_id>
    <nct_id>NCT03384329</nct_id>
  </id_info>
  <brief_title>Efficacy of Resveratrol in Depression</brief_title>
  <official_title>Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Russian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1)
      each morning daily for 1 month with primary outcome measures of the score change on
      depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times
      over the study period (before, in the middle, after the intervention, and in 2 week follow
      up).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline total score of HDRS-17</measure>
    <time_frame>at 1 month</time_frame>
    <description>Hamilton Depression Rating Scale 17 items, total score range 0-53 (53 - worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline SIRT1 enzymatic activity in the blood</measure>
    <time_frame>at 1 month</time_frame>
    <description>(enzyme sirtuin-1 activity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline total score of BDI-II</measure>
    <time_frame>at 1 month</time_frame>
    <description>Beck Depression Inventory 21 items, total score range 0-63 (63 - worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Resveratrol Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol Pill</intervention_name>
    <description>Resveratrol 500 mg</description>
    <arm_group_label>Resveratrol Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo Pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (selectively):

          -  MDD recurrent or with single episode with melancholic features or dysthymia (DSM-5);

          -  current depression.

        Exclusion Criteria (selectively):

          -  serious or unstable disease;

          -  antidepressants intake.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lyubomir I. Aftanas</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyubomir I. Aftanas, MD</last_name>
      <phone>3359855</phone>
      <phone_ext>(007)383</phone_ext>
      <email>liaftanas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Lyubomir I. Aftanas</investigator_full_name>
    <investigator_title>Director of the Institute of Physiology and Basic Medicine, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

